#Pharmasset

After making nearly $10 billion in 2014 with the hep C treatment Sovaldi, many of Gilead Sciences’ top developers have moved on to curing hepa...

Public documents from 2011 show that Pharmasset, the original developer of Sovaldi, initially estimated a price of $36,000 for the treatment.

Battle lines are drawn as the global health community prepares to face off with Big Pharma over the astronomic cost of treatment.

I am outraged that Gilead refuses to study 7977 with other DAAs that are farther along than their own drugs.

Pharmasset has announced plans to amend one of its Phase II clinical trials in the wake of liver toxicity concerns among some volunteers

The approval of two hepatitis C protease inhibitors, the first evidence of interferon-free regimens curing hep C, and more...

To the tune of 11 billion dollars, Gilead Sciences--a leader in HIV drug development and sales--has acquired one of the most talked-about phar...

A twelve-week course of Pharmasset?s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living...

Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage...

Pharmasset Inc. has started its Phase II clinical trial investigating the combination of its nucleotide polymerase inhibitor PSI-7977 and...

A combination of two experimental once-a-day drugs active against the hepatitis C virus (HCV) is showing excellent potential

Antiviral drug developer Pharmasset is gearing up to present â€œstartling resultsâ€ from its early clinical trial of two nucleotide a...